You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Researchers report promising results from a study examining a CRISPR-based treatment for sickle-cell disease, according to the Associated Press.
NPR reports that the first person in the US to undergo a CRISPR-based treatment for sickle-cell disease continues to do well nearly a year after treatment.
Nature Biotechnology discusses promising early results from two clinical trials of CRISPR-based therapy for β-thalassemia and sickle cell disease.
NPR reports that the patient who underwent a CRISPR-based treatment for sickle cell disease is doing well.
Doctors in the US have used CRISPR gene editing to try to treat a woman with sickle cell disease as part of a clinical trial, according to Popular Science.
US companies have begun recruiting for a CRISPR-based gene-editing trial to treat β-thalassemia, Stat News reports.
Vertex Pharmaceuticals has invested £10.5 million in the British analytics company as the companies launch a multiyear R&D partnership seeking novel drug targets.
In Science this week: pair of genomics studies on ancient animals, and more.
The partners will focus on developing gene editing-based treatments for cystic fibrosis and sickle cell disease, among other diseases.
Originally published Oct. 24.
According to BBC News, the global vaccine-sharing initiative has sent its first shipment, which arrived in Ghana this week.
CNN reports that a US Food and Drug Administration document says Johnson & Johnson's SARS-CoV-2 vaccine meets the requirements to receive an Emergency Use Authorization.
Researchers in France are developing a new, fast test for SARS-CoV-2 that initial testing indicates may be highly accurate, the Guardian says.
In Cell this week: analysis of fitness patterns among SARS-CoV-2 isolates, single-cell transcriptome analysis of immune features in COVID-19, and more.